

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-9 (Cancelled).

10. (New): An oral dosage form comprising:

(i) an erodable core which comprises the compound, 5-[4-[2-(N-methyl-N-(2 pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione or a pharmaceutically acceptable salt or solvate thereof, and another antidiabetic agent,

(ii) an erodable coating around said core, which coating comprises one or more openings leading to the core, wherein the coating is erodable under predetermined pH conditions.

11. (New): An oral dosage form according to claim 10, wherein the coating comprises one or more openings extending substantially completely through the coating but not substantially penetrating the core and communicating from the environment of use to the core and wherein release of the compound and the other antidiabetic agent from the core occurs substantially through the one or more openings and through erosion of the coating under pre-determined pH conditions.

12. (New): An oral dosage form according to claim 10, wherein the coating is an enteric coating.

13. (New): An oral dosage form according to claim 12, wherein the enteric coating is non-permeable.

14. (New): An oral dosage form according to claim 10, wherein the core is formulated to provide immediate release of both the compound and the other antidiabetic agent.

15. (New): An oral dosage form according to claim 10, wherein the other antidiabetic agent is metformin or a pharmaceutically acceptable salt or solvate thereof.

16. (New): An oral dosage form according to claim 10, wherein the dosage form is a tablet form.

17. (New): A process for the preparation of the oral dosage form according to claim 10, which process comprises:

- (a) preparing an erodable tablet core comprising the compound and another antidiabetic agent;
- (b) coating the core with a material with pH-dependent erodability; and
- (c) forming one or more openings in the coating.

18. (New): A method for the treatment of diabetes mellitus, metabolic syndrome, impaired glucose tolerance or impaired fasting glucose which method comprises administering the oral dosage form according to claim 10 to a human or non-human mammal in need thereof.